Why the study?
Does rivaroxaban 10 mg daily improve outcomes compared to an antiplatelet-based strategy in patients without an established indication for oral anticoagulation after successful TAVR?
Does rivaroxaban 10 mg daily improve outcomes compared to an antiplatelet-based strategy in patients without an established indication for oral anticoagulation after successful TAVR?
Routine use of rivaroxaban 10 mg daily after successful TAVR in patients without an indication for oral anticoagulation is harmful, increasing both thromboembolic/mortality risks and bleeding.
No takes yet. Share an insight, caveat, or question.
Rivaroxaban 10 mg daily should be avoided post-TAVR without OAC indication; confirms net harm versus antiplatelet strategy in this RCT.
Dangas et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: